Pierre Fabre Articles
Negative NICE final guidance for Pierre Fabre's Javlor in bladder cancer; fast-track FAD for Eliquis
23 January 2013
Pierre Fabre gains approval for fibromyalgia drug Joncia in Australia; TGA cancels approval for four painkillers
22 November 2011
Positive Ph III results for Forest Labs and Pierre Fabre’s levomilnacipran in major depressive disorder
18 July 2011
More negative opinions on cancer drugs from UK’s NICE
11 March 2011
Leadership changes at Eli Lilly, Pierre Fabre and China’s Simcere
14 February 2011
UK’s NICE gives initial thumbs down to Pierre Fabre’s Javlor for bladder cancer on the NHS
24 November 2010
Leadership changes at Biogen Idec, Exelixis, Abbott, Pierre Fabre; Shionogi reorganizes in USA
2 July 2010
B-MS halts vinflunine deal with Fabre
3 December 2007
LibraGen and PFM sign process development deal
16 January 2006
Merck & Co licenses Pierre Fabre's F50035
9 August 2004
B-MS licenses Pierre Fabre's Javlor
26 April 2004
Milnacipran enters Ph III for fibromyalgia
27 October 2003
Pierre Fabre's Javlor enters Ph III trials
22 September 2003
Pierr Fabre names Roch Doliveux as deputy DG
3 March 2003
SNIP Appointments
8 April 1998
Comarketing Deal for Milnacipran
13 January 1998
New Chemical Entities Round-Up For 1994
6 February 1995
MMD Launch In France
2 January 1995
First Approval Of Milnacipran
25 July 1994
NAVELBINE APPROVED IN CANADA
23 May 1994
NAVELBINE NEARING APPROVAL IN USA
9 May 1994
WELLCOME REFOCUSING R&D EFFORTS
10 May 1993
SINBIO LAUNCHES ANTIBIOTIC IN FRANCE
26 April 1993
NEW CANCER DRUGS SHINE AT US MEETING
2 November 1992
Showing 1-28 of 28 articles
- 1
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
